Treatment with Opdivo (nivolumab) after surgery significantly reduces the risk of disease recurrence or death in people with high-risk, muscle-invasive urothelial cancer — a form of bladder cancer — an interim analysis from a Phase 3 trial shows. The CheckMate -274 (NCT02632409) met its primary goals of extended disease-free survival both in the overall population and … Continue reading Post-surgery Opdivo Found to Reduce Risk of Recurrence in High-risk Bladder Cancer